Immutep Limited reported that its pivotal TACTI‑004 Phase III study—combining eftilagimod alfa (efti) with Merck’s KEYTRUDA® and chemotherapy—has reached the 50% enrollment target in first‑line non‑small cell lung cancer (NSCLC). The company has now enrolled 378 patients across 140 clinical sites in 27 countries, a pace that positions the trial to hit its full target of 756 patients by the third quarter of 2026.
The 50% milestone is a key operational achievement that de‑risks the trial’s data readout and demonstrates robust global recruitment. With 80 sites already activated in 25 countries, Immutep’s enrollment velocity supports its projected cash runway, which was A$99.1 million as of December 31 2025 and is expected to sustain operations into the second quarter of 2027.
Management highlighted the significance of the enrollment pace, noting that “the excellent pace of enrolment globally in the TACTI‑004 trial speaks to the promise of efti and the need for more efficacious therapies in the first‑line setting for patients with advanced/metastatic NSCLC.” The company also underscored that the upcoming futility analysis in the first quarter of 2026 and the completion of enrollment in the third quarter will be critical decision points for the trial’s progression.
Efti is a first‑in‑class MHC Class II agonist that activates antigen‑presenting cells, potentially expanding the benefit of anti‑PD‑1 therapy across all PD‑L1 expression levels. The TACTI‑004 design compares efti plus KEYTRUDA® and chemotherapy against KEYTRUDA® and chemotherapy alone, aiming to enroll patients regardless of PD‑L1 status. Positive data from earlier studies, such as INSIGHT‑003, have shown encouraging response rates in low‑ or no‑PD‑L1 patients, reinforcing the scientific rationale for the current trial.
The milestone also reinforces Immutep’s strategic partnership with Merck and its licensing deal with Dr. Reddy’s for emerging markets, positioning the company to capitalize on a large, high‑need oncology market. With a strong liquidity position and a low debt‑to‑equity ratio, the enrollment progress provides a buffer for continued investment in clinical development while maintaining financial flexibility.
Overall, the 50% enrollment achievement signals that Immutep is on track to deliver pivotal data that could establish a new standard of care in first‑line NSCLC, while simultaneously extending the company’s cash runway and setting the stage for the next critical milestones in the trial’s timeline.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.